MX375469B - Piroglutamato de vortioxetina. - Google Patents
Piroglutamato de vortioxetina.Info
- Publication number
- MX375469B MX375469B MX2017014390A MX2017014390A MX375469B MX 375469 B MX375469 B MX 375469B MX 2017014390 A MX2017014390 A MX 2017014390A MX 2017014390 A MX2017014390 A MX 2017014390A MX 375469 B MX375469 B MX 375469B
- Authority
- MX
- Mexico
- Prior art keywords
- vortioxetine pyroglutamate
- pyroglutamate
- vortioxetine
- salt
- pharmaceutical compositions
- Prior art date
Links
- 229960002263 vortioxetine Drugs 0.000 title abstract 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 title 1
- 229940043131 pyroglutamate Drugs 0.000 title 1
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- -1 vortioxetine pyroglutamate salt Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona sal de piroglutamato de vortioxetina y composiciones farmacéuticas que comprenden la sal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500284 | 2015-05-13 | ||
| PCT/EP2016/060540 WO2016180870A1 (en) | 2015-05-13 | 2016-05-11 | Vortioxetine pyroglutamate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017014390A MX2017014390A (es) | 2018-03-23 |
| MX375469B true MX375469B (es) | 2025-03-06 |
Family
ID=55963369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014390A MX375469B (es) | 2015-05-13 | 2016-05-11 | Piroglutamato de vortioxetina. |
Country Status (44)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45532A (fr) | 2016-07-01 | 2019-05-08 | H Lundbeck As | Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur |
| US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
| US11020390B2 (en) | 2017-02-17 | 2021-06-01 | Unichem Laboratories Ltd | Bioequivalent pharmaceutical composition of vortioxetine hydrobromide |
| CN111201217A (zh) * | 2017-07-31 | 2020-05-26 | 斯玛尔药物有限公司 | 羟基去甲氯胺酮的晶型 |
| GB201715950D0 (en) | 2017-10-02 | 2017-11-15 | Croda Int Plc | Gel composition comprising a phase change material |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| AU2021246973A1 (en) | 2020-04-03 | 2022-11-03 | H. Lundbeck A/S | 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1006728A (en) * | 1962-12-31 | 1965-10-06 | Mundipharma Ag | Amine salts of pyrrolidone carboxylic acid |
| JPS6160620A (ja) | 1984-09-03 | 1986-03-28 | Teijin Ltd | ピログルタミン酸エステル類を含有する医薬品組成物 |
| US4780667A (en) | 1985-06-25 | 1988-10-25 | Hewlett-Packard Company | Magnetostatic wave delay line discriminator with automatic quadrature setting and automatic calibration |
| FR2694194B1 (fr) | 1992-07-31 | 1994-11-04 | Health Business Dev | Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel. |
| DE59702733D1 (de) | 1996-08-15 | 2001-01-11 | Losan Pharma Gmbh | Gut schluckbare orale arzneiform |
| US6436946B1 (en) * | 1997-05-02 | 2002-08-20 | Morris A. Mann | Xanthine-containing compositions for oral administration and uses related thereto |
| SK284948B6 (sk) | 2000-04-06 | 2006-03-02 | Zentiva, A. S. | Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| JP5154924B2 (ja) | 2004-05-11 | 2013-02-27 | エガレット エイ／エス | ジェランガムを含む膨張可能な投与形態 |
| BR122020011920A2 (pt) * | 2006-06-16 | 2020-08-25 | Lundbeck & Co As H | composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| GEP20135938B (en) * | 2009-04-24 | 2013-10-10 | H Lundbeck As | Liquid pharmaceutical formulations of 1-[2-(2,4-dimethylsulfanyl)phenyl]piperazine |
| MX2012002199A (es) | 2009-08-24 | 2012-03-16 | Lundbeck & Co As H | Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]pip erazina. |
| WO2011136376A1 (ja) * | 2010-04-30 | 2011-11-03 | 武田薬品工業株式会社 | 腸溶性錠剤 |
| CN104797566B (zh) * | 2012-09-19 | 2017-07-07 | 桑多斯股份公司 | 沃替西汀氢溴酸盐的新结晶形式 |
| CN104995181B (zh) | 2013-02-22 | 2017-03-08 | H.隆德贝克有限公司 | 沃替西汀生产方法 |
-
2016
- 2016-05-10 JO JOP/2016/0091A patent/JO3456B1/ar active
- 2016-05-11 AU AU2016259762A patent/AU2016259762B2/en active Active
- 2016-05-11 TN TNP/2017/000453A patent/TN2017000453A1/en unknown
- 2016-05-11 EA EA201792262A patent/EA032363B1/ru not_active IP Right Cessation
- 2016-05-11 SI SI201630176T patent/SI3294719T1/sl unknown
- 2016-05-11 CA CA2984615A patent/CA2984615C/en active Active
- 2016-05-11 ES ES16721817T patent/ES2709362T3/es active Active
- 2016-05-11 IL IL255466A patent/IL255466B/en unknown
- 2016-05-11 CN CN201680025327.1A patent/CN107567440B/zh active Active
- 2016-05-11 MY MYPI2017001636A patent/MY184965A/en unknown
- 2016-05-11 CR CR20170506A patent/CR20170506A/es unknown
- 2016-05-11 KR KR1020177032520A patent/KR102551429B1/ko active Active
- 2016-05-11 SM SM20190053T patent/SMT201900053T1/it unknown
- 2016-05-11 DK DK16721817.1T patent/DK3294719T3/en active
- 2016-05-11 RU RU2017139002A patent/RU2713889C2/ru active
- 2016-05-11 PL PL16721817T patent/PL3294719T3/pl unknown
- 2016-05-11 MA MA043397A patent/MA43397A/fr unknown
- 2016-05-11 MX MX2017014390A patent/MX375469B/es active IP Right Grant
- 2016-05-11 PE PE2017002418A patent/PE20180039A1/es unknown
- 2016-05-11 WO PCT/EP2016/060540 patent/WO2016180870A1/en not_active Ceased
- 2016-05-11 GE GEAP201614622A patent/GEP20197020B/en unknown
- 2016-05-11 HK HK18111409.2A patent/HK1252099B/en unknown
- 2016-05-11 HR HRP20190089TT patent/HRP20190089T1/hr unknown
- 2016-05-11 ME MEP-2019-11A patent/ME03312B/me unknown
- 2016-05-11 TW TW105114554A patent/TWI700276B/zh not_active IP Right Cessation
- 2016-05-11 BR BR112017024039A patent/BR112017024039B8/pt active IP Right Grant
- 2016-05-11 EP EP16721817.1A patent/EP3294719B1/en active Active
- 2016-05-11 JP JP2017558957A patent/JP6731001B2/ja active Active
- 2016-05-11 HU HUE16721817A patent/HUE042893T2/hu unknown
- 2016-05-11 TR TR2019/01228T patent/TR201901228T4/tr unknown
- 2016-05-11 AR ARP160101356A patent/AR104591A1/es not_active Application Discontinuation
- 2016-05-11 RS RS20190108A patent/RS58263B1/sr unknown
- 2016-05-11 LT LTEP16721817.1T patent/LT3294719T/lt unknown
- 2016-05-11 PT PT16721817T patent/PT3294719T/pt unknown
- 2016-05-11 UA UAA201711057A patent/UA120779C2/uk unknown
- 2016-05-12 US US15/152,902 patent/US10287261B2/en active Active
-
2017
- 2017-10-27 ZA ZA2017/07337A patent/ZA201707337B/en unknown
- 2017-11-02 CO CONC2017/0011295A patent/CO2017011295A2/es unknown
- 2017-11-03 DO DO2017000260A patent/DOP2017000260A/es unknown
- 2017-11-03 SV SV2017005560A patent/SV2017005560A/es unknown
- 2017-11-07 PH PH12017502028A patent/PH12017502028A1/en unknown
- 2017-11-09 CL CL2017002844A patent/CL2017002844A1/es unknown
- 2017-11-10 EC ECIEPI201774919A patent/ECSP17074919A/es unknown
-
2019
- 2019-01-24 CY CY20191100089T patent/CY1121171T1/el unknown
- 2019-03-06 US US16/294,647 patent/US11279682B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3015585C (en) | Pth prodrugs | |
| CL2016002772A1 (es) | Composiciones de insulina de rápida acción | |
| BR112018008901A2 (pt) | formulações subcutâneas de anticorpos anti-cd 38 e seus usos | |
| EP3305103A4 (en) | atomizing | |
| DOP2017000260A (es) | Piroglutamato de vortioxetina | |
| GEP20217239B (en) | Pharmaceutical composition | |
| EP3315035A4 (en) | atomizing | |
| HUE059623T2 (hu) | Páraképzõ rendszer | |
| DK3655017T3 (da) | Farmaceutisk sammensætning | |
| BR112016018062A8 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| FI3753929T3 (fi) | Dimeerisiä varjoaineita | |
| BR112016016274A2 (pt) | Ponte da barreira hematoencefálica | |
| EP3265098A4 (en) | COMPOSITIONS FOR MODULATING THE MECP2 EXPRESSION | |
| GEP20217240B (en) | Pharmaceutical composition | |
| DK3582629T3 (da) | Marinade | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| IL265680B (en) | Dimeric contrast agents | |
| EP3682016A4 (en) | FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS | |
| SMT202400478T1 (it) | Composizione farmaceutica | |
| ES1216222Y (es) | Composicion que comprende cenizas de cremacion | |
| EP3463589A4 (en) | PERFUME DISTRIBUTION SYSTEM | |
| EP3675918C0 (fr) | Systeme de diffusion de fragrances | |
| DK3096839T3 (da) | Duftende sammensætninger til kroppen | |
| ES2747993T8 (es) | Composiciones farmacéuticas de liberación prolongada de levetiracetam | |
| EP3585279A4 (en) | SURGICAL VISUALIZATION SYSTEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |